Varicella zoster virus (VZV) is the cause of chickenpox (varicella) and shingles (zoster), and was once responsible for over 4 million infections in the United States annually. The development of a live attenuated VZV vaccine was initially viewed with extreme skepticism. Nonetheless, a VZV vaccine was developed in the 1970s by Takahashi and his colleagues in Japan and was eventually licensed in the US. It is now known to be one of the safest and most effective vaccines available and is administered worldwide. Here are described important factors that contributed to the successful research and licensure of the highly successful VZV vaccine.
Get full access to this article
View all access options for this article.
References
1.
AAP. American Academy of Pediatrics Committee on Infectious Diseases: the use of oral acyclovir in otherwise healthy children with varicella. Pediatrics, 1993; 91:674–676.
2.
Amlie-LefondC, and GildenD. Varicella zoster virus: a common cause of stroke in children and adults. J Stroke Cerebrovasc Dis, 2016; 25:1561–1569.
3.
ArvinA, and GildenD. Molecular mechanisms of varicella zoster virus pathogenesis. In: KnipeD, HowleyP, ed. Fields Virology. 6th ed. Philadelphia: Lippincott, Williams, and Wilkins. 2013:2015–2057.
4.
AsanoY, SugaS, YoshikawaT, et al.Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics, 1994; 94:524–526.
5.
BaxterR, RayP, TranTN, et al.Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study. Pediatrics, 2013; 131:e1389–e1396.
6.
BaxterR, TranTN, RayP, et al.Impact of vaccination on the epidemiology of varicella: 1995–2009. Pediatrics, 2014; 134:24–30.
7.
BialekSR, PerellaD, ZhangJ, et al.Impact of a routine two-dose varicella vaccination program on varicella epidemiology. Pediatrics, 2013; 132:e1134–e1140.
8.
BirleaM, NagelMA, KhmelevaN, et al.Varicella-zoster virus trigeminal ganglioneuritis without rash. Neurology, 2014; 82:90–92.
9.
BrissonM, GayN, doWJ, and AndrewsNJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine, 2002; 20:2500–2507.
10.
BrunellP, RossA, MillerL, and KuoB. Prevention of varicella by zoster immune globulin. J Engl J Med, 1969; 280:1191–1194.
11.
BrunellPA. Live varicella vaccine. Lancet, 1975; i:98.
12.
BrunellPA. Varicella vaccine: the crossroads is where we are not! Pediatrics. 1978; 62:858–859.
13.
Centers for DiseaseC, Prevention. Outbreak of invasive group A Streptococcus associated with varicella in a childcare center—Boston, Massachusetts, 1997. MMWR Morb Mortal Wkly Rep, 1997; 46:944–948.
14.
ChavesSS, HaberP, WaltonK, et al.Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infect Dis, 2008; 197Suppl 2:S170–S177.
15.
ChenJJ, ZhuZ, GershonAA, and GershonMD. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell, 2004; 119:915–926.
16.
CohenJI. The varicella-zoster virus genome. Curr Top Microbiol Immunol, 2010; 342:1–14.
17.
CunninghamAL, LalH, KovacM, et al.Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med, 2016; 375:1019–1032.
18.
DohnerDE, AdamsSG, and GelbLD. Recombination in tissue culture between varicella-zoster virus strains. J Med Virol, 1988; 24:329–341.
19.
EndersG, MillerE, Cradock-WatsonJ, BolleyI, and RidehalghM. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet, 1994; 343:1548–1551.
GershonA. Varicella. In WatsonP, GershonA, OxmanMN, eds. Herpes Zoster: Postherpetic Neuralgia and Other Compllications. Switzerland: Elsevier/Adis, 2017:pp. 7–15.
22.
GershonA, LaRussaP, and SteinbergS. Varicella vaccine: use in immunocompromised patients. In WhiteJ, EllisR, eds. Infectious Disease Clinics of North America, vol. 10. Philadelphia: Saunders, 1996:583–594.
23.
GershonA, TakahashiM, and SewardJF. Live attenuated varicella vaccine. In PlotkinS, OrensteinW, OffitP, eds. Vaccines, vol. 6th ed. Philadelphia: WB Saunders, 2013:837–869.
24.
GershonAA, ChenJ, DavisL, et al.Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children. Trans Am Clin Climatol Assoc, 2012; 123:17–33.
25.
GershonAA, ChenJ, and GershonMD. Use of saliva to identify varicella-zoster virus (VZV) infection of the gut. Clin Infect Dis, 2015; 61:536–544.
26.
GershonAA, and GershonMD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev, 2013; 26:728–743.
27.
GershonAA, SteinbergS, GelbL; NIAID-Collaborative-Varicella-Vaccine-Study-Group. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA, 1984; 252:355–362.
28.
GildenDH, Kleinschmidt-DeMastersBK, LaGuardiaJJ, MahaliinghamR, and CohrsRJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med, 2000; 342:635–645.
29.
GroseC, EdmondBJ, and BrunellPA. Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis, 1979; 139:432–437.
30.
HardyI, GershonAA, SteinbergSP, et al.The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med, 1991; 325:1545–1550.
31.
Hope-SimpsonRE. The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med, 1965; 58:9–20.
32.
IzawaT, IharaT, HattoriA, et al.Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics, 1977; 60:805–809.
33.
KawaiK, YawnBP, WollanP, and HarpazR. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis, 2016; 63:221–226.
34.
KempeCH, GershonAA. Varicella vaccine at the crossroads. Pediatrics, 1977; 60:930–931.
35.
KleinNP, FiremanB, YihWK, et al.Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics, 2010; 126:e1–e8.
36.
KleinNP, LewisE, BaxterR, et al.Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics, 2012; 129:809–814.
37.
LalH, CunninghamAL, GodeauxO, et al.Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med, 2015; 372:2087–2096.
38.
LeungJ, and HarpazR. Impact of the maturing varicella vaccination program on varicella and related outcomes in the United States: 1994–2012. J Pediatric Infect Dis Soc, 2016; 5:395–402.
39.
LeungJ, HarpazR, BaughmanAL, et al.Evaluation of laboratory methods for diagnosis of varicella. Clin Infect Dis, 2010; 51:23–32.
40.
LoparevVN, RubtcovaEN, BostikV, et al.Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol, 2007; 81:12758–12765.
41.
LopezAS, ZhangJ, and MarinM. Epidemiology of varicella during the 2-dose varicella vaccination program—United States, 2005–2014. MMWR Morb Mortal Wkly Rep, 2016; 65:902–905.
42.
MaglioneMA, DasL, RaaenL, et al.Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics, 2014; 134:325–337.
43.
MalavigeGN, JonesL, BlackAP, and OggGS. Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol, 2008; 152:522–531.
44.
MarinM, GurisD, ChavesSS, SchmidS, and SewardJF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2007; 56:1–40.
45.
MichalikDE, SteinbergSP, LaRussaPS, et al.Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis, 2008; 197:944–949.
46.
NagelMA, and GildenD. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol, 2014; 27:356–360.
47.
OxmanMN, LevinMJ, JohnsonGR, et al.A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 2005; 352:2271–2284.
48.
PetersGA, TylerSD, GroseC, et al.A full-genome phylogenetic analysis of varicella-zoster virus reveals a novel origin of replication-based genotyping scheme and evidence of recombination between major circulating clades. J Virol, 2006; 80:9850–9860.
QuinlivanML, JensenNJ, RadfordKW, and SchmidDS. Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster. J Clin Microbiol, 2012; 50:1533–1538.
51.
SaimanL, LaRussaP, SteinbergS, et al.Persistence of immunity to varicella-zoster virus vaccination among health care workers. Infect Control Hosp Epidemiol, 2001; 22:279–283.
52.
ShapiroED, VazquezM, EspositoD, et al.Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis, 2011; 203:312–315.
53.
SharrarRG, LaRussaP, GaleaS, et al.The postmarketing safety profile of varicella vaccine. Vaccine, 2000; 19:916–923.
54.
ShawJ, HalseyNA, WeinbergA, et al.Arm paralysis after routine childhood vaccinations: application of advanced molecular methods to the causality assessment of an adverse event after immunization. J Pediatric Infect Dis Soc, 2017; 6:e161–e164.
55.
TakahashiM, AsanoY, KamiyaH, BabaK, and YamanishiK. Active immunization for varicella-zoster virus. In: NahmiasA, DowdleW, SchinaziR, eds. The Human Herpesviruses. New York: Elsevier, 1981:414–431.
56.
TakahashiM, OtsukaT, OkunoY, AsanoY, YazakiT, and IsomuraS. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet, 1974; 2:1288–1290.
57.
ThieleS, BorschewskiA, KuchlerJ, BieberbachM, VoigtS, and EhlersB. Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions. Clin Vaccine Immunol, 2011; 18:1058–1066.
58.
VazquezM, LaRussaPS, GershonAA, et al.Effectiveness over time of varicella vaccine. JAMA, 2004; 291:851–855.
59.
WatsonB, LauferD, KuterB, StaehleB, and WhiteCJ. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (RRRIIV) in healthy children. J Infect Dis, 1996; 173:731–734.
60.
WatsonJC, HadlerSC, DykewiczCA, et al.Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 1998; 47:1–57.
61.
WeinmannS, ChunC, SchmidDS, et al.Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis, 2013; 208:1859–1868.
62.
WhartonM. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am, 1996; 10:571–581.
63.
WhiteCJ. Clinical trials of varicella vaccine in healthy children. Infect Dis Clin North Am, 1996; 10:595–608.
64.
WilliamsV, GershonA, and BrunellPA. Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis, 1974; 130:669–672.
65.
YamanishiK. Molecular analysis of the Oka vaccine strain of varicella-zoster virus. J Infect Dis, 2008; 197Suppl 2:S45–S48.
